Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?

被引:14
作者
Buss, Vera H. [1 ]
Lee, Kayla [1 ]
Naunton, Mark [1 ]
Peterson, Gregory M. [1 ,2 ]
Kosari, Sam [1 ]
机构
[1] Univ Canberra, Fac Hlth, Bruce, ACT 2617, Australia
[2] Univ Tasmania, Sch Med, Sandy Bay, TAS 7005, Australia
关键词
QT interval prolongation; torsade de pointes; medication review; pharmacist intervention; DE-POINTES; PROLONGING MEDICATIONS; PHARMACIST; KNOWLEDGE;
D O I
10.3390/jcm7120533
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prolongation of the QT interval is a relatively rare but serious adverse drug reaction. It can lead to torsade de pointes, which is potentially life-threatening. The study's objectives were: determine the use of QT interval-prolonging drugs in an elderly community-dwelling population at risk of medication misadventure and identify recommendations regarding the risk of QT interval prolongation made by pharmacists when performing medication reviews. In a retrospective evaluation, 500 medication review reports from Australian pharmacists were analysed. In patients taking at least one QT interval-prolonging drug, the individual risk of drug-induced QT interval prolongation was assessed. Recommendations of pharmacists to avoid the occurrence of this drug-related problem were examined. There was a high prevalence of use of potentially QT interval-prolonging drugs (71% patients), with 11% of patients taking at least one drug with a known risk. Pharmacists provided specific recommendations in only eight out of 35 patients (23%) with a high-risk score and taking drugs with known risk of QT interval prolongation. Pharmacists' recommendations, when present, were focused on drugs with known risk of QT interval prolongation, rather than patients' additional risk factors. There is a need to improve knowledge and awareness of this topic among pharmacists performing medication reviews.
引用
收藏
页数:7
相关论文
共 17 条
[1]  
Ahn J, 2015, AUST FAM PHYSICIAN, V44, P249
[2]   A survey of health care practitioners' knowledge of the QT interval [J].
Al-Khatib, SM ;
LaPointe, NMA ;
Kramer, JM ;
Chen, AY ;
Hammill, BG ;
Delong, L ;
Califf, RM .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 (05) :392-396
[3]   QTc prolongation in acute medical admissions: an often overlooked and potentially serious finding [J].
Coughlan, John Joseph ;
Wafer, Meghan ;
Fitzgerald, Gearoid ;
Nawaz, Aamir ;
O'Brien, Claire ;
Liston, Richard .
POSTGRADUATE MEDICAL JOURNAL, 2018, 94 (1108) :123-+
[4]  
CredibleMeds, QTDrugs list
[5]  
Dhanani TC, 2017, INT J PHARM PRACT, V25, P176, DOI 10.1111/ijpp.12303
[6]  
Hutchins Lisa M, 2017, J Pediatr Pharmacol Ther, V22, P399, DOI 10.5863/1551-6776-22.6.399
[7]   Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice [J].
Isbister, Geoffrey K. ;
Page, Colin B. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (01) :48-57
[8]   Knowledge deficits related to the QT interval could affect patient safety [J].
LaPointe, NMA ;
Al-Khatib, SM ;
Kramer, JM ;
Califf, RM .
ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2003, 8 (02) :157-160
[9]   Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: A pilot study [J].
Ng, Tien Mh ;
Bell, Adrienne M. ;
Hong, Chandra ;
Hara, Jill M. ;
Touchette, Daniel R. ;
Danskey, Karine N. ;
Lindsay, Tanya T. ;
Puumala, Susan E. .
ANNALS OF PHARMACOTHERAPY, 2008, 42 (04) :475-482
[10]  
Pharmaceutical Society of Australia, 2011, GUID PHARM PROV HOM, P1